Vertex and crispr therapeutics announce global exa-cel regulatory submissions for sickle cell disease and beta thalassemia in 2022

Boston & zug, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) today announced that vertex has concluded discussions with the u.s. food and drug administration (fda), and the fda granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (scd) and transfusion-dependent beta thalassemia (tdt). vertex will submit its biologics licensing application (bla) for exa-cel for rolli
VRTX Ratings Summary
VRTX Quant Ranking